Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Development of an Induction Peptide Expression in the Nervous System: Administration of Synthetic or Purified Peptides Directly Into the Brain
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID: 1526
Administration of synthetic or purified peptides directly into the brain ventricles is a method commonly used by neuroscientists for exploring physiological and behavioural functions of gene products. Intra-ventricle...
Contact
Participants
You
Email me a copy of this message
Introduction/Background

Administration of synthetic or purified peptides directly into the brain ventricles is a method commonly used by neuroscientists for exploring physiological and behavioural functions of gene products. Intra-ventricle administration is controlled by the blood-brain barrier, which limits its effectiveness, and currently available methods for the delivery of peptides or pharmacological agents into the cerebrospinal fluid (CSF) in the brain present researchers with limitations, concerning both the natural properties of the delivered substance (solubility, stability, synthesis, purifications, etc) and the experimental needs (prolonged and/or repeated administration, inducible delivery, minimal handling of the experimental animals, etc).

Aims/Hypothesis

We aim to develop an effective method for introducing peptides into the brain.

Research

The choroid plexus is a blood-CSF barrier, composed of epithelial cells, that plays a critical role in the mechanism regulating the exchange of molecules between the brain's internal milieu and the periphery. Neuromodulators directed to CSF can modify and adapt a variety of behavioural, neuroendocrine, and immunologic processes. The proposed technology is a lentiviral-based system which uses a choroid plexus specific promoter. The functionality of this system was demonstrated by using the over-expression of the two established neuropeptides. This technology may prove as a powerful tool for addressing research questions involving acute or chronic effects of gene products within the CNS.

This flexible system can easily be adapted for various methods such as chronic exposure, inducible expression, and minimal handling of animals, as well as alleviating the need for complex synthesis and purification protocols and the use of expensive micropumps.

Conclusion

The current technology utilizes a genetic approach for the specific delivery of secreted peptides or proteins into the CSF.

Relevance/Opportunity

Please enquire regarding licensing or codevelopment partnerships quoting reference no. 1526.
FEATURED
Last Updated May 2015
Technology Type PLATFORM
Phase of Development PRECLINICAL
CORPORATION